Rec'd PCT/PTO 06 FEB 2000

"Express Mail" Label No. <u>EV 724261659 US</u>

Date of Deposit: February 6, 2006

Attorney Docket No.: 016325-013800US

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Mail Stop: PCT Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ALLAN et al.

Application No.: 10/516,803

Filed:

For: METHODS OF DIAGNOSING AND TREATING DIABETES AND INSULIN RESISTANCE

Examiner: Not yet assigned

Art Unit: Not yet assigned

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR §1.97 and

§1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references [in compliance with the requirements of 37 CFR §1.98(a)(2)] are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the Search/Examination report corresponding to the PCT application.

ALLAN et al.

Application No.: 10/516,803

Page 2

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

lean M. Lockyer, Ph.D. Reg. No. 44,879

TOWNSEND and TOWNSEND and CREW LLP

Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 415-576-0200 Fax: 415-576-0300

JML:mcd 60696596 v1

Substitute for form 1449A/PTO		Complete if Known			
		•	Application Number	10/516,803	
INFORMATION	ON DISCLO	SURE	Filing Date		
STATEMENT BY APPLICANT			First Named Inventor	Allan, Bernard	
			Art Unit	Not yet assigned	
(Use as many sheets as necessary)			Examiner Name	Not yet assigned	
Sheet 1	of	2	Attorney Docket Number	016325-013800US	

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ^{2 (F known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		US-			***		
		US-					
***************************************	4	US-					
***************************************		US-	***************************************				
		US-					
		US-					

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document		Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	⊤ 6		
		Country Code ³	Number⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	1,	
	A1	wo	00/00506		01/06/2000	Sagami Chemical Research Center	_		
**************************************	A2	wo	01/57221	A2	08/09/2001	Ceptyr, Inc.			
	АЗ	wo	01/97850	A2	12/27/2001	Schering Aktiengesellschaft			
		:							

Examiner	Date	
Signature	Considered	
J.3		

Substitute for form 1449B/PTO				Complete if Known			
				Application Number	10/516,803		
INF	FORMATION D	ISCLOS	URE	Filing Date			
ST	STATEMENT BY APPLICANT			First Named Inventor	Allan, Bernard		
				Art Unit	Not yet assigned		
	(Use as many sheets	as necessary)		Examiner Name	Not yet assigned		
Sheet	2	of	2	Attorney Docket Number	016325-013800US		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
	A4	KOLLE, G. et al., "CRIM1, a novel gene encoding a cysteine-rich repeat protein, is developmentally regulated and implicated in vertebrate CNS development and organogenesis," Mechanisms of Development (2000) 90: 181-193				
	A 5	LI, Duanxiang, et al., "Human protein tyrosine phosphatase-like gene: expression profile, genomic structure, and mutation analysis in families with ARVD," Gene (2000) 256: 237-243				
	·					

	'	-		
Examiner			Date	
Signature	·		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.